HIV-1
Clinical trials for HIV-1 explained in plain language.
Never miss a new study
Get alerted when new HIV-1 trials appear
Sign up with your email to follow new studies for HIV-1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can antibodies flush out hidden HIV? new trial aims to find out
Disease control OngoingThis study tests whether two lab-made antibodies, 3BNC117-LS and 10-1074-LS, can safely reduce the hidden HIV reservoir in people already on suppressive antiretroviral therapy (ART). The trial involves 105 adults with HIV who will receive three infusions of the antibodies or a pl…
Matched conditions: HIV-1
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for Drug-Resistant HIV: early access to TMC125
Disease control APPROVED_FOR_MARKETINGThis study provides early access to the experimental drug TMC125 (etravirine) for HIV-1 patients who have failed multiple treatments and have few options left. Participants take TMC125 along with other antiretroviral drugs chosen by their doctor. The study tracks safety and how w…
Matched conditions: HIV-1
Sponsor: Tibotec Pharmaceuticals, Ireland • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental HIV vaccine trial aims to boost immunity in people on suppressive therapy
Disease control TerminatedThis phase 1 trial tests a new therapeutic HIV vaccine (CH505 TF chTrimer) in 30 adults living with HIV who are on suppressive antiretroviral therapy. The vaccine is designed to stimulate the immune system to produce new antibodies against HIV. The study is currently suspended an…
Matched conditions: HIV-1
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC